Fresolimumab, a humanized anti-TGF-β antibody, has shown positive results regarding SSc20, while nintedanib, a tyrosine kinase inhibitor (blocking PDGF), has been tested and approved for SSc with interstitial lung disease (ILD)21. Here, TGFB1 is linked to interstitial lung disease.